The Flawed Study Behind Calls for Abortion Pill Restrictions
What: Reason critiques anti-abortion study methodology—misclassified cases and inflated ER stats.
Key Line: “No matter how a pregnancy ends, a pregnant woman incurs some risk.”
Cancer incidence among women continues to rise despite overall progress.
WHI funding restored after backlash; $140 saved for every dollar spent, researchers say.
National Geographic explores ovarian aging research and why it matters.
Interleukin-6 shows early promise in detecting life-threatening sepsis.
Even with dye bans, ultra-processed food remains the real issue, The Atlantic argues.
Meta-analysis finds prenatal cannabis use raises risks of preterm and low birth weight.
Estrogen’s role in the brain goes far beyond reproduction, NYT reports.
Hormone therapy may lower a genetic heart risk factor, new WHI data suggests.
Syphilis cases surged 80%; treatment gaps tied to stillbirth and NICU stays.
Young women now outpace young men in binge drinking, a reversal from previous years.
ADF targets birth control and IUD coverage in campaign to cut ties with ACOG.
New Yorker review highlights how fetal rights are becoming the next legal front.
Right-leaning outlet calls out bad data used to attack abortion pills.
Cosmo breaks down Botox alternatives—and why your injector matters most.
Year-long birth control prescriptions could cut unintended pregnancies and save money, says R Street.
Estrogen’s role in the brain goes far beyond reproduction, NYT reports.
New GLP-1 pill for diabetes patients shows 7%+ weight loss, boosting Eli Lilly stock.
Study finds no mass OBGYN flight from states with abortion bans—yet.
DOJ says states can’t overrule FDA—even as future restrictions loom.
Trump promotes IVF access while cutting the team responsible for tracking it.